Dr. Reddy’s Laboratories Ltd ADR (RDY) revenue breakdown
By segment, Global Generics is the largest at 89% of fiscal 2026 revenue, growing 11% a year over 9 years.
By region, Others is the largest at 35% of fiscal 2026 revenue, growing 15% a year over 9 years.
Revenue by segment
Fiscal years, as Dr. Reddy’s Laboratories Ltd ADR reports them in its 10-K filings; fiscal 2026 total $335.9B.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Generics | $115.4B | $114.0B | $122.9B | $138.1B | $154.4B | $179.2B | $213.8B | $245.5B | $289.6B | $299.0B | 89% |
| Pharmaceutical Services and Active Ingredients | $21.3B | $22.0B | $24.1B | $25.7B | $32.0B | $30.7B | $29.1B | $29.8B | $33.8B | $34.8B | 10% |
| Other segment | — | — | — | — | $3.3B | $4.5B | $3.0B | $3.9B | $2.1B | $2.1B | 1% |
| Proprietary products | $2.4B | $4.2B | $4.8B | $7.9B | — | — | — | — | — | — | — |
| Others | $1.8B | $1.8B | $2.1B | $2.8B | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Dr. Reddy’s Laboratories Ltd ADR reports them in its 10-K filings; fiscal 2026 total $335.9B.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | $34.5B | $36.1B | $40.4B | $49.6B | $61.0B | $69.0B | $67.5B | $72.8B | $94.4B | $118.7B | 35% |
| UNITED STATES | $69.8B | $68.1B | $69.3B | $76.0B | $76.7B | $80.6B | $106.7B | $135.6B | $149.4B | $117.9B | 35% |
| India | $24.9B | $25.2B | $28.8B | $32.1B | $36.3B | $44.0B | $50.5B | $48.5B | $55.8B | $64.5B | 19% |
| Russia | $11.5B | $12.6B | $15.3B | $16.9B | $15.8B | $20.9B | $21.2B | $22.3B | $26.0B | $34.8B | 10% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for RDY.
Open RDY in InvestinglyQuestions
Where does Dr. Reddy’s Laboratories Ltd ADR make its money?
In fiscal 2026, by segment: Global Generics $299.0B, Pharmaceutical Services and Active Ingredients $34.8B, Other segment $2.1B.
From Dr. Reddy’s Laboratories Ltd ADR's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.